Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61

Kazuhiko Kurozumi; Jayson Hardcastle; Roopa Thakur; Joshua Shroll; Michal Nowicki; Akihiro Otsuki; E. Antonio Chiocca; Balveen Kaur

doi:10.1038/mt.2008.112

Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61

Kazuhiko Kurozumi, Jayson Hardcastle, Roopa Thakur, Joshua Shroll, Michal Nowicki, Akihiro Otsuki, E. Antonio Chiocca, Balveen Kaur

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

Oncolytic viral therapy is under evaluation for toxicity and efficacy in clinical trials relating to several different tumors. We report a significant increase in the angiogenic index of oncolytic virus (OV)-treated glioma-matrigel implants (2.83-fold, P < 0.02). In a rat intracranial glioma model, large tumors from OV-treated animals were significantly more angiogenic than the phosphate-buffered saline (PBS)-treated control tumors (OV: 101 ± 21.6; PBS: 19.8 ± 10; P = 0.0037). Transcript profiling of OV-treated tumors revealed dysregulation of several transcripts involved in glioma angiogenesis. OV-mediated induction of CYR61 gene expression (8.94-fold, P = 0.001) correlated significantly with the presence of OV in tumor tissue in vivo (R = 0.7, P < 0.001). Further, induction of CYR61 mRNA and protein were confirmed in multiple human cancer cell lines and primary human tumor-derived cells in vitro, and in tumor lysate and cerebrospinal fluid (CSF) in vivo. Finally, we show that treatment of glioma cells with Cilengitide, known to counter CYR61-induced integrin activation, significantly suppressed the proangiogenic effect of OV treatment of gliomas (P < 0.05).

Original language	English (US)
Pages (from-to)	1382-1391
Number of pages	10
Journal	Molecular Therapy
Volume	16
Issue number	8
DOIs	https://doi.org/10.1038/mt.2008.112
State	Published - Aug 2008
Externally published	Yes

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology
Genetics
Pharmacology
Drug Discovery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/mt.2008.112

Cite this

@article{fcb98d5d98de4c2f834093b6f3730b90,

title = "Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61",

abstract = "Oncolytic viral therapy is under evaluation for toxicity and efficacy in clinical trials relating to several different tumors. We report a significant increase in the angiogenic index of oncolytic virus (OV)-treated glioma-matrigel implants (2.83-fold, P < 0.02). In a rat intracranial glioma model, large tumors from OV-treated animals were significantly more angiogenic than the phosphate-buffered saline (PBS)-treated control tumors (OV: 101 ± 21.6; PBS: 19.8 ± 10; P = 0.0037). Transcript profiling of OV-treated tumors revealed dysregulation of several transcripts involved in glioma angiogenesis. OV-mediated induction of CYR61 gene expression (8.94-fold, P = 0.001) correlated significantly with the presence of OV in tumor tissue in vivo (R = 0.7, P < 0.001). Further, induction of CYR61 mRNA and protein were confirmed in multiple human cancer cell lines and primary human tumor-derived cells in vitro, and in tumor lysate and cerebrospinal fluid (CSF) in vivo. Finally, we show that treatment of glioma cells with Cilengitide, known to counter CYR61-induced integrin activation, significantly suppressed the proangiogenic effect of OV treatment of gliomas (P < 0.05).",

author = "Kazuhiko Kurozumi and Jayson Hardcastle and Roopa Thakur and Joshua Shroll and Michal Nowicki and Akihiro Otsuki and Chiocca, {E. Antonio} and Balveen Kaur",

note = "Funding Information: This work was supported by funding from the National Institutes of Health Grant (1K01NS059575 to B.K.; R01NS064607 to B.K.; P01 CA069246 to E.A.C.); The OSUCCC, Viral Oncogenesis Program seed grant (to B.K.); American Association for Neurological Surgeons/ Congress of Neurological Surgeons, Section on Tumors/BrainLAB International Research Fellowship (to K.K.); American Brain tumor Association Medical student fellowship (to J.S.); The Deans undergraduate research fund (to R.T.).",

year = "2008",

month = aug,

doi = "10.1038/mt.2008.112",

language = "English (US)",

volume = "16",

pages = "1382--1391",

journal = "Molecular Therapy",

issn = "1525-0016",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61

AU - Kurozumi, Kazuhiko

AU - Hardcastle, Jayson

AU - Thakur, Roopa

AU - Shroll, Joshua

AU - Nowicki, Michal

AU - Otsuki, Akihiro

AU - Chiocca, E. Antonio

AU - Kaur, Balveen

N1 - Funding Information: This work was supported by funding from the National Institutes of Health Grant (1K01NS059575 to B.K.; R01NS064607 to B.K.; P01 CA069246 to E.A.C.); The OSUCCC, Viral Oncogenesis Program seed grant (to B.K.); American Association for Neurological Surgeons/ Congress of Neurological Surgeons, Section on Tumors/BrainLAB International Research Fellowship (to K.K.); American Brain tumor Association Medical student fellowship (to J.S.); The Deans undergraduate research fund (to R.T.).

PY - 2008/8

Y1 - 2008/8

N2 - Oncolytic viral therapy is under evaluation for toxicity and efficacy in clinical trials relating to several different tumors. We report a significant increase in the angiogenic index of oncolytic virus (OV)-treated glioma-matrigel implants (2.83-fold, P < 0.02). In a rat intracranial glioma model, large tumors from OV-treated animals were significantly more angiogenic than the phosphate-buffered saline (PBS)-treated control tumors (OV: 101 ± 21.6; PBS: 19.8 ± 10; P = 0.0037). Transcript profiling of OV-treated tumors revealed dysregulation of several transcripts involved in glioma angiogenesis. OV-mediated induction of CYR61 gene expression (8.94-fold, P = 0.001) correlated significantly with the presence of OV in tumor tissue in vivo (R = 0.7, P < 0.001). Further, induction of CYR61 mRNA and protein were confirmed in multiple human cancer cell lines and primary human tumor-derived cells in vitro, and in tumor lysate and cerebrospinal fluid (CSF) in vivo. Finally, we show that treatment of glioma cells with Cilengitide, known to counter CYR61-induced integrin activation, significantly suppressed the proangiogenic effect of OV treatment of gliomas (P < 0.05).

AB - Oncolytic viral therapy is under evaluation for toxicity and efficacy in clinical trials relating to several different tumors. We report a significant increase in the angiogenic index of oncolytic virus (OV)-treated glioma-matrigel implants (2.83-fold, P < 0.02). In a rat intracranial glioma model, large tumors from OV-treated animals were significantly more angiogenic than the phosphate-buffered saline (PBS)-treated control tumors (OV: 101 ± 21.6; PBS: 19.8 ± 10; P = 0.0037). Transcript profiling of OV-treated tumors revealed dysregulation of several transcripts involved in glioma angiogenesis. OV-mediated induction of CYR61 gene expression (8.94-fold, P = 0.001) correlated significantly with the presence of OV in tumor tissue in vivo (R = 0.7, P < 0.001). Further, induction of CYR61 mRNA and protein were confirmed in multiple human cancer cell lines and primary human tumor-derived cells in vitro, and in tumor lysate and cerebrospinal fluid (CSF) in vivo. Finally, we show that treatment of glioma cells with Cilengitide, known to counter CYR61-induced integrin activation, significantly suppressed the proangiogenic effect of OV treatment of gliomas (P < 0.05).

UR - http://www.scopus.com/inward/record.url?scp=48349119172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48349119172&partnerID=8YFLogxK

U2 - 10.1038/mt.2008.112

DO - 10.1038/mt.2008.112

M3 - Article

C2 - 18545226

AN - SCOPUS:48349119172

SN - 1525-0016

VL - 16

SP - 1382

EP - 1391

JO - Molecular Therapy

JF - Molecular Therapy

IS - 8

ER -

Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this